Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.26 Insider Own42.69% Shs Outstand5.67M Perf Week-5.69%
Market Cap73.26M Forward P/E- EPS next Y-3.56 Insider Trans0.00% Shs Float3.25M Perf Month54.91%
Income-8.13M PEG- EPS next Q-0.62 Inst Own5.75% Short Float1.25% Perf Quarter30.11%
Sales1.53M P/S47.88 EPS this Y- Inst Trans-3.37% Short Ratio1.79 Perf Half Y115.33%
Book/sh1.69 P/B7.66 EPS next Y- ROA-42.39% Short Interest0.04M Perf Year48.51%
Cash/sh1.84 P/C7.03 EPS next 5Y- ROE-48.36% 52W Range4.14 - 18.50 Perf YTD69.33%
Dividend Est.- P/FCF- EPS past 5Y65.00% ROI-84.93% 52W High-30.16% Beta1.41
Dividend TTM- Quick Ratio4.81 Sales past 5Y0.00% Gross Margin- 52W Low212.08% ATR (14)1.51
Dividend Ex-Date- Current Ratio4.81 EPS Y/Y TTM37.34% Oper. Margin-883.26% RSI (14)54.18 Volatility9.31% 12.76%
Employees13 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-532.67% Recom1.00 Target Price33.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q66.11% Payout- Rel Volume1.20 Prev Close13.73
Sales Surprise- EPS Surprise26.32% Sales Q/Q- EarningsNov 13 BMO Avg Volume22.70K Price12.92
SMA203.50% SMA5028.84% SMA20073.96% Trades Volume27,193 Change-5.90%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Canaccord Genuity Buy $50
Nov-17-20Downgrade H.C. Wainwright Buy → Neutral
Mar-21-18Initiated H.C. Wainwright Buy $1.25
Feb-21-24 08:00AM
Feb-20-24 10:22AM
Feb-12-24 08:00AM
Feb-07-24 08:30AM
07:00AM Loading…
Feb-06-24 07:00AM
Feb-05-24 08:00AM
Jan-10-24 07:00AM
Jan-09-24 07:00AM
Jan-05-24 08:00AM
Nov-13-23 07:00AM
Oct-30-23 11:21AM
Oct-25-23 02:50PM
Oct-24-23 07:00AM
Oct-18-23 07:00AM
07:00AM Loading…
Oct-05-23 07:00AM
Sep-18-23 10:40AM
Sep-05-23 07:00AM
Aug-21-23 08:16AM
Aug-15-23 04:01PM
Mar-30-23 07:00AM
Dec-16-22 06:30AM
Dec-05-22 06:30AM
Dec-01-22 07:55AM
Nov-17-22 05:20PM
Nov-14-22 04:01PM
Oct-25-22 06:30AM
Aug-17-22 08:52AM
Aug-11-22 06:48PM
07:30AM Loading…
Jul-26-22 07:30AM
Jun-23-22 07:30AM
May-20-22 08:10AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 04:05PM
May-04-22 07:20AM
Apr-18-22 10:42AM
Apr-11-22 07:20AM
Apr-08-22 07:20AM
Apr-06-22 10:15AM
Mar-23-22 10:20AM
Mar-21-22 07:20AM
Mar-09-22 04:56AM
Feb-24-22 07:02AM
Dec-20-21 07:02AM
Dec-16-21 08:59AM
Dec-01-21 07:02AM
Nov-30-21 11:57AM
Nov-29-21 06:27AM
Nov-22-21 07:02AM
Nov-10-21 07:02AM
Oct-28-21 07:30AM
Sep-10-21 07:02AM
Sep-09-21 07:32AM
Sep-08-21 07:32AM
Aug-30-21 07:32AM
Aug-19-21 06:05AM
Aug-11-21 07:32AM
Aug-06-21 10:20AM
Jul-06-21 06:34AM
Jun-30-21 11:14AM
Jun-28-21 08:35AM
Jun-21-21 08:35AM
Jun-18-21 07:35AM
Jun-13-21 06:13PM
May-14-21 08:21AM
May-10-21 10:23AM
Mar-25-21 11:47AM
Mar-18-21 07:05AM
Mar-17-21 07:05AM
Mar-14-21 04:47AM
Mar-04-21 04:05PM
Feb-18-21 04:05PM
Feb-17-21 04:13PM
Feb-16-21 09:18AM
Feb-11-21 10:02PM
Jan-11-21 07:30AM
Dec-04-20 07:20AM
Nov-29-20 07:29PM
Nov-18-20 11:55AM
Nov-12-20 04:02PM
Oct-19-20 08:00AM
Sep-24-20 08:00AM
Sep-17-20 03:40PM
Sep-15-20 07:12AM
Sep-11-20 08:30AM
Sep-10-20 08:00AM
Sep-08-20 04:02PM
Sep-01-20 04:02PM
Aug-24-20 08:32AM
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in 2001 and is headquartered in Boston, MA.